7.49
0.17 (2.32%)
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Jade Biosciences, Inc. | Menaik | - |
AISkor Stockmoo
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | 3.5 |
Osilator Teknikal | -0.5 |
Purata | 1.63 |
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 0.04% |
% Dimiliki oleh Institusi | 33.40% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Allostery Investments Lp | 31 Mar 2025 | 40,614 |
Intech Investment Management Llc | 30 Jun 2025 | 22,995 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 18.00 (Wedbush, 140.32%) | Beli |
Median | 16.00 (113.62%) | |
Rendah | 14.00 (Guggenheim, 86.92%) | Beli |
Purata | 16.00 (113.62%) | |
Jumlah | 2 Beli | |
Harga Purata @ Panggilan | 6.88 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Wedbush | 14 Aug 2025 | 18.00 (140.32%) | Beli | 6.77 |
Guggenheim | 16 Jun 2025 | 14.00 (86.92%) | Beli | 6.99 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
13 Aug 2025 | Pengumuman | Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
08 Jul 2025 | Pengumuman | Jade Biosciences to Participate in Two Upcoming Investor Conferences |
01 Jul 2025 | Pengumuman | Jade Biosciences Appoints Brad Dahms as Chief Financial Officer |
09 Jun 2025 | Pengumuman | Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy |
02 Jun 2025 | Pengumuman | Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |